Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ripasudil in Retinopathy of Prematurity
NCT04621136Phase 2Completed
- Sponsor
- Kyushu University
- Start
- Nov 2020
- Primary completion
- Nov 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ripasudil in retinopathy of prematurity (ROP), sponsored by Kyushu University. Primary endpoint: Proportion of patients with Adverse Events(AEs) and Adverse Drug Reactions(ADRs). Started Nov 2020; status: completed.
02
Drugs
ripasudil
03
Conditions
retinopathy of prematurity (ROP)
Beyond the preview
Go deeper on NCT04621136.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04621136.